Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 4, 2025, details two significant capital raising transactions completed by Guardant Health, Inc. The filings cover a Common Stock Offering and a Convertible Notes Offering, with closing dates occurring on November 7, 2025.
Key Financial Metrics and Capital Structure
- Common Stock Offering: The Company sold 3,833,332 shares of common stock at a public offering price of $90.00 per share. This included the full exercise of an underwriters' option to purchase an additional 499,999 shares.
- Net Proceeds (Equity): Approximately $327.2 million after deducting underwriting discounts and estimated offering expenses.
- Convertible Notes Offering: The Company issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033. This included the full exercise of an option to purchase an additional $52.5 million principal amount.
- Net Proceeds (Debt): Approximately $390.0 million after deducting initial purchasers' discounts and estimated offering expenses.
- Total Capital Raised: Approximately $717.2 million in combined net proceeds.
- Note Terms: The Notes bear no regular interest, do not accrete, and mature on May 15, 2033. The initial conversion price is approximately $121.50 per share (a ~35% premium to the stock offering price).
Material Changes and Use of Proceeds
The Company increased the size of both offerings from previously announced figures ($250.0 million for equity and $300.0 million for notes). The net proceeds from both transactions are designated for general corporate purposes. Specifically, management indicated that proceeds may be used, depending on market conditions, to repurchase a portion of the Company's existing 0% convertible senior notes due 2027.
Outlook, Risks, and Contingencies
- Conversion Mechanics: The 2033 Notes are convertible only under specific circumstances, including if the stock price exceeds 130% of the conversion price for a specified period, or upon certain corporate events. Holders may convert freely only after February 15, 2033.
- Redemption Rights: The Company may not redeem the Notes before November 20, 2029. Redemption is permitted thereafter only if the stock price exceeds 130% of the conversion price.
- Dilution Potential: Up to 4,472,217 shares of common stock may be issued upon conversion of the Notes based on the initial conversion rate, subject to anti-dilution adjustments.
- Events of Default: The Indenture outlines standard events of default, including payment failures, bankruptcy, and failure to comply with reporting covenants. Certain reporting covenant defaults have a 365-day cure period where the sole remedy is the accrual of special interest.
Investor Verification Checklist
- Verify the exact closing date of November 7, 2025, and confirm the final net proceeds received.
- Review the specific terms of the 2027 notes to assess the likelihood and timing of a potential repurchase using the new proceeds.
- Monitor the Company's stock price relative to the $121.50 conversion price to evaluate the risk of future dilution from the 2033 Notes.
- Confirm the impact of the new debt issuance on the Company's overall leverage ratios and liquidity position.
- Check for any subsequent filings regarding the actual execution of the 2027 note repurchase program.